US Patent

US8436180 — Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof

Composition of Matter · Assigned to Bayer Intellectual Property GmbH · Expires 2033-08-26 · 7y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridine-3-carboxamides and their use in treating and preventing diseases, especially cardiovascular disorders.

USPTO Abstract

The present application relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridine-3-carboxamides, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

Drugs covered by this patent

Patent Metadata

Patent number
US8436180
Jurisdiction
US
Classification
Composition of Matter
Expires
2033-08-26
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Bayer Intellectual Property GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.